Clinical Research & Reference Standard Compendium
CJC-1295 + Ipamorelin Spray - Scientific Literature
I. Abstract & Overview
CJC-1295 + Ipamorelin is a two-component research blend that engages the growth hormone axis at two independent receptors. CJC-1295 is a 29-residue analog of growth hormone-releasing hormone carrying four engineered substitutions; Jetté and colleagues characterized the albumin-bioconjugate approach in 2005, and Teichman and colleagues reported prolonged growth hormone and IGF-1 secretion in 2006. Ipamorelin is a five-residue ghrelin receptor agonist described by Raun and colleagues in 1998, notable because it released growth hormone without the corticotropin and prolactin elevation characteristic of earlier secretagogues. Because the two receptors couple through different G proteins, the pairing allows a single preparation to raise both cAMP and intracellular calcium in somatotroph models. Research Use Only (RUO).
II. Chemical Specifications
| Molecular Formula | Blend — no single formula applies; a 29-residue GHRH analog combined with Ipamorelin (C38H49N9O5) |
|---|---|
| Molar Mass | Ipamorelin 711.9 g/mol; CJC-1295 3367.9 g/mol without DAC or 3647.2 g/mol with DAC — confirm which form and the blend ratio with manufacturer COA |
| CAS Registry Number | Blend |
| Amino Acid Sequence | Two-peptide blend: a 29-residue tetrasubstituted GHRH analog combined with Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) — verify the CJC-1295 form and blend ratio with manufacturer COA |
III. Mechanism & Cellular Signaling Pathways
The two components converge on growth hormone release from opposite directions. CJC-1295 activates the GHRH receptor, a class B G protein-coupled receptor, coupling through Gs to adenylyl cyclase; the resulting cAMP activates protein kinase A, which phosphorylates CREB and drives Pit-1 expression, sustaining transcription of the growth hormone gene. That arm therefore increases synthesis, not only release. Ipamorelin activates the ghrelin receptor, which couples instead through Gq to phospholipase C, generating inositol trisphosphate that releases calcium from intracellular stores and triggers fusion of secretory vesicles. Research shows Ipamorelin also reduces inhibitory somatostatin tone. Combining two GHRH analogs would produce competition for one receptor; combining a GHRH analog with a ghrelin receptor agonist produces engagement of two.
IV. Primary Research Directions
- **Dual Second Messenger Readout:** Research shows cAMP and intracellular calcium can be tracked simultaneously in one somatotroph preparation, since the two arms couple through different G proteins.
- **Additive Versus Synergistic Testing:** Laboratory investigations run each component alone in adjacent wells, the only design that establishes whether the combined growth hormone response exceeds the sum of its parts.
- **Prolonged Secretion Profile:** Teichman and colleagues (2006) reported sustained growth hormone and IGF-1 elevation from the GHRH analog, giving a time-course dimension the pentapeptide alone does not provide.
- **Secretagogue Selectivity:** Raun and colleagues (1998) established that Ipamorelin releases growth hormone without the corticotropin and prolactin response of GHRP-6, which is why it is the partner of choice.
- **Somatostatin Tone Studies:** Research shows the ghrelin receptor arm reduces inhibitory somatostatin signaling, a variable isolatable by comparing blend against single-component responses.
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.' Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. DOI: 10.1210/jc.2005-1536 | PMID: 16352683
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). 'Ipamorelin, the first selective growth hormone secretagogue.' European Journal of Endocrinology, 139(5), 552-561. DOI: 10.1530/eje.0.1390552 | PMID: 9849822
- Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). 'A receptor in pituitary and hypothalamus that functions in growth hormone release.' Science, 273(5277), 974-977. DOI: 10.1126/science.273.5277.974 | PMID: 8688086
CJC-1295 + Ipamorelin Spray
Abstract & Overview
CJC-1295 + Ipamorelin is a two-component research blend that engages the growth hormone axis at two independent receptors. CJC-1295 is a 29-residue analog of growth hormone-releasing hormone carrying four engineered substitutions; Jetté and colleagues characterized the albumin-bioconjugate approach in 2005, and Teichman and colleagues reported prolonged growth hormone and IGF-1 secretion in 2006. Ipamorelin is a five-residue ghrelin receptor agonist described by Raun and colleagues in 1998, notable because it released growth hormone without the corticotropin and prolactin elevation characteristic of earlier secretagogues. Because the two receptors couple through different G proteins, the pairing allows a single preparation to raise both cAMP and intracellular calcium in somatotroph models. Research Use Only (RUO).
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (CJC-1295 + Ipamorelin Spray) | 7.60 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 7.60 minutes represents the active compound (CJC-1295 + Ipamorelin Spray). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
The two components converge on growth hormone release from opposite directions. CJC-1295 activates the GHRH receptor, a class B G protein-coupled receptor, coupling through Gs to adenylyl cyclase; the resulting cAMP activates protein kinase A, which phosphorylates CREB and drives Pit-1 expression, sustaining transcription of the growth hormone gene. That arm therefore increases synthesis, not only release. Ipamorelin activates the ghrelin receptor, which couples instead through Gq to phospholipase C, generating inositol trisphosphate that releases calcium from intracellular stores and triggers fusion of secretory vesicles. Research shows Ipamorelin also reduces inhibitory somatostatin tone. Combining two GHRH analogs would produce competition for one receptor; combining a GHRH analog with a ghrelin receptor agonist produces engagement of two.
Primary Research Directions
**Dual Second Messenger Readout:** Research shows cAMP and intracellular calcium can be tracked simultaneously in one somatotroph preparation, since the two arms couple through different G proteins.
**Additive Versus Synergistic Testing:** Laboratory investigations run each component alone in adjacent wells, the only design that establishes whether the combined growth hormone response exceeds the sum of its parts.
**Prolonged Secretion Profile:** Teichman and colleagues (2006) reported sustained growth hormone and IGF-1 elevation from the GHRH analog, giving a time-course dimension the pentapeptide alone does not provide.
**Secretagogue Selectivity:** Raun and colleagues (1998) established that Ipamorelin releases growth hormone without the corticotropin and prolactin response of GHRP-6, which is why it is the partner of choice.
**Somatostatin Tone Studies:** Research shows the ghrelin receptor arm reduces inhibitory somatostatin signaling, a variable isolatable by comparing blend against single-component responses.
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.' Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. DOI: 10.1210/jc.2005-1536 | PMID: 16352683
Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). 'Ipamorelin, the first selective growth hormone secretagogue.' European Journal of Endocrinology, 139(5), 552-561. DOI: 10.1530/eje.0.1390552 | PMID: 9849822
Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). 'A receptor in pituitary and hypothalamus that functions in growth hormone release.' Science, 273(5277), 974-977. DOI: 10.1126/science.273.5277.974 | PMID: 8688086
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
